Centessa Insider Locks In $168K via Option Exercise & Share Sale
Rhea-AI Filing Summary
Centessa Pharmaceuticals (NASDAQ: CNTA) Form 4 shows General Counsel Iqbal J. Hussain exercised 12,000 stock options at $5.84 and immediately sold the same number of ordinary shares at a weighted-average $14.02 on 06/24/2025 under a Rule 10b5-1 plan.
Post-transaction, Hussain’s direct ownership declined by ~10% to 105,386 shares; he also holds 5,500 shares indirectly and 291,559 unexercised options.
- Gross sale proceeds ≈ $168.2 K.
- Sale represents >5% of insider’s pre-sale direct holdings, meeting materiality threshold.
- No impact on share count or dilution.
Insider selling by a senior legal officer can be viewed as a potential sentiment headwind, though execution under a pre-arranged 10b5-1 plan mitigates timing concerns.
Positive
- None.
Negative
- General Counsel sold 12,000 shares (~10% of direct stake) for approximately $168K, a potential negative insider-sentiment signal
Insights
GC exercises options, then sells 12k shares; 10% stake trim merits watch.
The $5.84 option exercise followed by a $14.02 sale locks in a 140% gain, netting roughly $168k. While the cash amount is modest, divesting over 5% of direct holdings triggers many insider-sell alert thresholds and may weigh on sentiment. The Rule 10b5-1 plan offers procedural cover, yet such plans often allow strategic flexibility. Hussain still retains 105,386 shares plus 291,559 unexercised options, indicating ongoing alignment. Market impact should be limited unless this sale precedes a pattern of continued disposals; investors should monitor future Form 4s for confirmation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (right to buy) | 12,000 | $0.00 | -- |
| Exercise | Ordinary Shares | 12,000 | $5.84 | $70K |
| Sale | Ordinary Shares | 12,000 | $14.0182 | $168K |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
